Clinical Trials Logo

Clinical Trial Summary

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. This study will evaluate how well risankizumab works compared to ustekinumab. This study will assess change in Crohn's Disease Activity Index (CDAI). Risankizumab is an investigational drug being developed for the treatment of Crohn's Disease (CD). Ustekinumab is an approved drug for the treatment of moderate and severe CD. Participants are randomly assigned to one of the three treatment groups. Each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to ustekinumab. Around 508 adult participants with moderate to severe CD will be enrolled in approximately 307 sites worldwide. In Part 1, participants assigned to risankizumab will receive intravenous (IV) doses of risankizumab at Week 0, 4,8 and subcutaneous (SC) doses every 8 weeks thereafter through Week 48. Participants assigned to ustekinumab will receive intravenous (IV) dose of ustekinumab at Week 0 and subcutaneous (SC) doses every 8 weeks thereafter through Week 48. In Part 2, participants who received risankizumab in Part 1 and completed the Week 48 visit will continue to receive SC risankizumab for up to an additional 220 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04524611
Study type Interventional
Source AbbVie
Contact
Status Active, not recruiting
Phase Phase 3
Start date September 30, 2020
Completion date February 15, 2028

See also
  Status Clinical Trial Phase
Completed NCT02778464 - Faecal Calprotectin as a Potential Non-invasive Inflammatory Marker in Pregnancy and Inflammatory Bowel Disease
Terminated NCT02775656 - UCB Cimzia Pregnancy Follow-up Study
Active, not recruiting NCT02782663 - A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease Phase 2
Completed NCT02108821 - Fecal Microbiota Transplantation in Pediatric Patients Phase 1
Completed NCT04089514 - A Real-world Study of Imraldi® Use
Completed NCT01364896 - Anal Human Papillomavirus in Inflammatory Bowel Disease Study
Completed NCT04271748 - The Impact of Time Restricted Feeding in Crohn's Disease N/A
Completed NCT03801928 - Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel Disease
Recruiting NCT04779320 - A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) Phase 3
Completed NCT01877577 - Supplementation of Vitamin D3 in Patients With Inflammatory Bowel Diseases and Hypovitaminosis D N/A